Effects of sitagliptin combined with metformin on islet function, glucose and lipid metabolism and adipokines in obese patients with type 2 diabetes mellitus

Abstract

Objective To investigate the effects of sitagliptin combined with metformin on the islet function, glucose and lipid metabolism and adipokines in obese patients with type 2 diabetes mellitus (T2DM). Methods A total of 94 obese patients with T2DM treated in Tengzhou Central People’s Hospital from January 2014 to May 2016 were randomly divided into control group and observation group, with 47 cases in each group. Patients in control group were treated with metformin, and patients in observation group were treated with sitagliptin and metformin. The two groups were given 6 months of treatment. Body mass index (BMI), levels of blood glucose, blood lipids, insulin and adipokines before and after treatment were determined, and the incidence of adverse reactions was statistically analyzed. Results After 6 months of treatment, BMI, waist circumference, body fat percentage (FAT), total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), fasting plasma glucose (FPG), 2 h postprandial plasma glucose (2 h PG), glycosylated hemoglobin (HbA1c), fasting insulin (FINS), insulin resistance index (HOMA-IR) and visfatin (Vfn) were decreased in the two groups (P 0.05. Conclusions Sitagliptin combined with metformin can decrease levels of blood glucose and blood lipid, improve insulin resistance, enhance the function of pancreatic β cells and regulate the expression of adipokines in obese patients with T2DM. Key words: Type 2 diabetes mellitus; Obesity; Islet function; Glucose metabolism; Lipid metabolism; Sitagliptin